Co-Diagnostics, Inc. (NASDAQ:CODX) Sees Large Growth in Short Interest

Posted by George Bondi on Jun 15th, 2026

Co-Diagnostics, Inc. (NASDAQ:CODX – Get Free Report) saw a significant increase in short interest in May. As of May 29th, there was short interest totaling 349,389 shares, an increase of 79.9% from the May 14th total of 194,179 shares. Based on an average daily trading volume, of 34,775,288 shares, the short-interest ratio is currently 0.0 days. Currently, 10.0% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in Co-Diagnostics by 40.4% during the fourth quarter. Geode Capital Management LLC now owns 449,148 shares of the company’s stock valued at $81,000 after purchasing an additional 129,158 shares in the last quarter. Jane Street Group LLC raised its position in Co-Diagnostics by 314.1% during the second quarter. Jane Street Group LLC now owns 166,254 shares of the company’s stock valued at $47,000 after purchasing an additional 126,105 shares in the last quarter. Finally, Virtu Financial LLC increased its holdings in shares of Co-Diagnostics by 393.8% during the third quarter. Virtu Financial LLC now owns 126,524 shares of the company’s stock worth $44,000 after buying an additional 100,901 shares in the last quarter. 14.99% of the stock is currently owned by institutional investors and hedge funds.

Co-Diagnostics Trading Down 9.2%

NASDAQ CODX traded down $0.40 during midday trading on Monday, hitting $3.90. The company had a trading volume of 260,638 shares, compared to its average volume of 3,720,962. The company has a market capitalization of $14.37 million, a PE ratio of -0.25 and a beta of 2.70. The firm has a 50-day moving average price of $3.12 and a 200-day moving average price of $4.18. Co-Diagnostics has a twelve month low of $1.26 and a twelve month high of $46.50.

Co-Diagnostics (NASDAQ:CODX – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($4.06) EPS for the quarter, missing the consensus estimate of ($3.75) by ($0.31). Co-Diagnostics had a negative net margin of 6,760.63% and a negative return on equity of 164.92%. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.13 million.

Wall Street Analyst Weigh In

A number of research firms have commented on CODX. Weiss Ratings lowered Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Wall Street Zen raised Co-Diagnostics to a “sell” rating in a report on Saturday, May 23rd. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $67.50.

Check Out Our Latest Research Report on Co-Diagnostics

About Co-Diagnostics

(Get Free Report)

Co-Diagnostics, Inc is a molecular diagnostics company headquartered in Salt Lake City, Utah, known for its proprietary CoPrimer™ technology. Founded in 2016, the company focuses on the design, development and distribution of molecular diagnostic test kits for the detection of infectious diseases, genetic mutations and other health-relevant biomarkers. Its core platform leverages patented cooperative primers, which are engineered to enhance specificity, sensitivity and cost-effectiveness compared to conventional PCR-based assays.

Through its in-house manufacturing and global supply chain partnerships, Co-Diagnostics produces a range of real-time polymerase chain reaction (qPCR) kits, reagents and customized assay development services.